HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC

Clinical trial NCT07045558 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07045558
Sponsor: RenJi Hospital
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Unresectable Hepatocellular Carcinoma

Start date: 2025-08-01
Primary completion: 2026-07-31
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.